Aratana Therapeutics, Inc. (NASDAQ: PETX) is a fast-growing pet therapeutics company headquartered in Kansas City, Kansas with offices in Boston, Massachusetts, San Diego, California and Leuven, Belgium. Aratana intends to become the leader in pet therapeutics by developing, manufacturing and marketing products that address the unmet medical needs of pets.
The company acquires or develops proprietary, patent-protected compounds and advances them through clinical studies to regulatory approval for use in pets. Following registration, the prescription pet therapeutics will be marketed to veterinarians who will use them to safely and effectively manage pets’ medical needs, resulting in longer and improved quality of life for pets.
Aratana anticipates up to six therapeutic product marketing authorizations by 2016 and currently has more than eighteen products in development. Aratana currently has two products that are in the commercialization phase, which are monoclonal antibodies to aid in the treatment of T-cell and B-cell lymphoma in dogs.